迈克生物股份有限公司 证券代码:300463 证券简称:迈克生物 公告编号:2023-020 第 1 页 共 2 页 证券代码:300463 证券简称:迈克生物 公告编号:2023-020 关于举办 2022 年度业绩说明会并征集相关问题的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 迈克生物股份有限公司（以下简称"迈克生物"或"公司"）《2022年年度报告》及其摘要将 于2023年4月25日在巨潮资讯网（http://www.cninfo.com.cn）披露。 为了让广大投资者进一步了解公司2022年年度经营业绩情况，公司拟定于2023年4月28日 （星期五）15:00-17:00在价值在线举办2022年度业绩说明会，本次年度业绩说明会将采用网络 远程的方式举行，投资者可登陆价值在线（https://eseb.cn/13YENl1raVO）参与本次年度业绩说 明会。 出席本次说明会的人员有：公司总经理吴明建、市场运营总监胥胜国、财务总监尹珊、董 事会秘书史炜、独立董事傅代国、保荐代表人鄢坚。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩 ...

编号：2015-IR002 证券代码:300463 证券简称:迈克生物 四川迈克生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 类别 | ■ \n□ \n□ 现场参观 \n□ | 特定对象调研 □分析师会议 \n媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n其他 （请文字说明其他活动内容） | | 参与单位名称 | | 西南证券、方正证券、中金公司、国金证券、广发证券、华创证券、国投瑞银、 上投摩根、工银瑞信、大成基金、宝盈基金、红土创新、南方基金、金鹰基金、 | | | | | | | | 长盛基金、前海开源基金等机构的 150 余位参会人员 ...

编号：2015-IR001 证券代码:300463 证券简称:迈克生物 四川迈克生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 类别 | ■ \n□ \n■ 现场参观 \n□ | 特定对象调研 □分析师会议 \n媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n其他 （请文字说明其他活动内容） | | 参与单位名称 | 申万宏源证券、泰康资产、 | IDG 资本 、长城公募基金、长盛公募基金、上海鼎 锋资产管理有限公司、深 ...

编号：2018-IR001 证券代码:300463 证券简称:迈克生物 迈克生物股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 类别 | ■ \n□ \n□ 现场参观 □ | 特定对象调研 □分析师会议 \n媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n其他 （请文字说明其他活动内容） | | 参与单位名称 | 人员 | 华安基金、中欧瑞博基金、博时裕益基金、先锋基金、广发基金、海富通、 泰康资产、嘉实基金、工银瑞信、天风证券、国泰君安等机构的 15 位参会 | | | | | | 时间 | 2018 年 1 月 25 | 日 9:30~12:00 | | 地点 ...

编号：2019-001 证券代码：300463 证券简称：迈克生物 迈克生物股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------|----------------------------|------------------------------------------------------------------------------------------------------------------| | | | | | | □ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | ☑ | 其他 深交所 投资者服务丝路行（四川站）走进迈克生物 | | 参与单位名称 | 1 2 | 、通过国金证券、宏信证券、华西证券等报名的近 36 名投资者； 、全景网、证券时报、第一财经广播记者等 7 人； | | 及人员姓名 | 3 | 、深交所及四川省上市公司协会相关领导。 | | 时间 | 2019 年 8 月 15 | 日上 ...

Group 1: Company Overview and Performance - Maccura achieved a revenue of 370,365.38 million yuan in 2020, representing a growth of 14.91% compared to the previous year [2] - The company reported a net profit of 79,542.03 million yuan, an increase of 51.43% year-on-year [2] - Basic earnings per share reached 1.4303 yuan, up by 50.65% from the previous year [2] Group 2: COVID-19 Product Development - Maccura developed COVID-19 testing products across three platforms: molecular diagnostics, chemiluminescence immunoassay, and rapid testing [2] - The molecular diagnostic platform's nucleic acid testing reagents received NMPA registration in March 2020, followed by CE certification and FDA EUA [2] - The company faced significant gaps in sales compared to other molecular diagnostic companies, but successfully streamlined its supply chain and achieved mass production within 2-3 months [2] Group 3: Market Strategy and Future Outlook - Maccura's strategy focuses on a "full product line, full industry chain" approach, which has allowed for rapid product development and market adaptation [3] - The company plans to expand its chemiluminescence immunoassay product line, with 51 registered reagents and a target of over 140 in the future [4] - The immunodiagnostics market, currently with a domestic market share of less than 30%, is expected to grow rapidly, driven by national policies supporting domestic manufacturers [4] Group 4: Stock Issuance Plans - Maccura received approval from the China Securities Regulatory Commission for a specific stock issuance on February 8, 2021, and is currently in the roadshow and investor interest assessment phase [6] - The company has not yet determined a specific issuance timeline, which will depend on market conditions and regulatory requirements [6]

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 15%[20] - The company's revenue for the first half of 2022 was ¥1,781,810,340.82, a decrease of 9.11% compared to ¥1,960,373,333.89 in the same period last year[32] - Net profit attributable to shareholders was ¥405,770,027.70, down 23.68% from ¥531,681,926.41 in the previous year[32] - Basic earnings per share decreased by 29.65% to ¥0.6728 from ¥0.9563 in the same period last year[32] - The company achieved a revenue of 1.782 billion, a year-on-year decrease of 9.11%, and a net profit of 406 million, down 23.68%[55] - Sales revenue from self-developed products was 1.136 billion, a decline of 1.84%, while agency product sales revenue was 626 million, down 20.17%[55] Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of 2023[20] - The company emphasizes overseas market expansion, having established partnerships with over 460 distributors across 112 countries and regions, making international markets a key area for growth[46] - The company is focused on expanding its market presence and enhancing its product offerings in the molecular diagnostics sector, particularly in digital PCR technology[153] - The company plans to enhance its competitive edge by improving product quality, variety structure, R&D capabilities, and sales services in response to increasing market competition[156] Research and Development - The company has allocated 50 million RMB for research and development in new technologies for the upcoming fiscal year[20] - The company invested 12.33 million yuan in R&D during the reporting period, marking a 10.94% increase year-on-year[78] - The company has established a research and development platform that includes two major centers for reagents and instruments, focusing on continuous technological breakthroughs and new technology reserves[48] - The company has 480 ongoing R&D projects, with 135 new projects initiated in the first half of 2022[81] - R&D investment for the period amounted to approximately 123.31 million RMB, with significant allocations across various product lines[81] Product Development and Innovation - The company plans to launch three new products in the next quarter, focusing on advanced diagnostic technologies[20] - The company has developed a digital PCR product line under the molecular diagnostics platform, leveraging droplet microfluidics technology, with a focus on creating fully automated, integrated digital PCR instruments and associated reagents[46] - The company is developing a fully automated biochemical analyzer aimed at enhancing product competitiveness and is currently in the development phase[84] - The company has completed the development of urine transferrin assay kits and improved kidney function testing menu, aiming to enhance product performance and brand influence in biochemical products[87] Financial Management - No cash dividends will be distributed to shareholders for this fiscal year, as the company focuses on reinvestment[6] - The company has received non-public offering funds, resulting in a significant increase in cash and cash equivalents by 4,137.57% to ¥649,626,367.67[115] - The total investment amount for the reporting period was ¥482,323,024.91, representing an increase of 88.74% compared to ¥255,547,835.69 in the same period last year[127] - The company has allocated ¥31,000.00 million of idle raised funds to purchase bank wealth management products[135] Environmental Responsibility - The company has established a wastewater treatment station that operates normally, with total emissions of ammonia nitrogen at 0.0889 tons/year and COD at 0.7707 tons/year[177] - The company has a new emergency response plan for environmental incidents, valid until July 3, 2025[182] - The company has implemented wastewater monitoring at treatment plant outlets, measuring parameters such as flow, pH, suspended solids, and biochemical oxygen demand, with a frequency of once per season[190] - There were no administrative penalties due to environmental issues during the reporting period, indicating compliance with regulations[192] Corporate Governance and Social Responsibility - The company has established a strong corporate culture and talent team, which are essential for its long-term development and competitive advantage[96] - The company is actively involved in community service and environmental initiatives, reflecting its commitment to social responsibility[195] - The company has engaged in multiple investor communications to discuss its business performance and future strategies[166] - The company has committed to long-term stockholding and will adhere to regulations regarding stock reduction post-lockup period, with a maximum of 25% of shares held being sold annually[199]

Financial Performance - Revenue for Q1 2022 was ¥924,725,004.03, a decrease of 13.54% compared to ¥1,069,535,881.25 in the same period last year[4] - Net profit attributable to shareholders was ¥201,843,094.15, down 35.58% from ¥313,335,250.80 year-on-year[4] - Basic earnings per share decreased by 39.77% to ¥0.3399 from ¥0.5643 in the previous year[4] - Total operating revenue for the first quarter was ¥924,725,004.03, down 13.5% from ¥1,069,535,881.25 in the previous year[32] - Net profit for the quarter was ¥212,187,393.54, a decrease of 35.5% compared to ¥329,384,972.57 in the same period last year[35] - The net profit attributable to the parent company was approximately ¥201.84 million, a decrease from ¥313.34 million in the previous period, representing a decline of about 35.5%[38] - The total comprehensive income attributable to the parent company was approximately ¥201.84 million, down from ¥313.34 million, reflecting a decrease of around 35.5%[38] Cash Flow - Net cash flow from operating activities increased by 38.57% to ¥120,108,068.54, compared to ¥86,679,373.91 in the same period last year[4] - Cash flow from operating activities generated a net amount of approximately ¥120.11 million, an increase from ¥86.68 million in the previous period, representing a growth of about 38.5%[42] - Cash flow from investing activities resulted in a net outflow of approximately ¥1.07 billion, compared to a net outflow of ¥119.35 million in the previous period[45] - Cash flow from financing activities generated a net inflow of approximately ¥1.26 billion, contrasting with a net outflow of ¥15.96 million in the previous period[45] - The ending balance of cash and cash equivalents was approximately ¥926.38 million, an increase from ¥534.76 million in the previous period, reflecting a growth of about 73%[45] - The company received cash from investment of approximately ¥940 million during the investment activities[45] - The company reported a cash inflow from operating activities totaling approximately ¥821.86 million, down from ¥1.02 billion in the previous period, indicating a decrease of about 19%[42] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,002,274,266.41, an increase of 21.86% from ¥6,566,894,132.48 at the end of the previous year[4] - Total liabilities decreased to ¥1,690,901,202.58 from ¥2,025,164,897.83, a reduction of 16.5%[30] - The company's equity attributable to shareholders increased to ¥6,057,872,980.64, up from ¥4,298,573,450.85, marking a growth of 41.0%[30] - Short-term borrowings decreased significantly to ¥335,097,332.92 from ¥530,557,969.20, a reduction of 36.8%[30] - Deferred tax assets increased to ¥163,971,729.56 from ¥161,183,123.70, indicating stable tax planning[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 44,218[12] - The largest shareholder, Tang Yong, holds 11.11% of shares, totaling 68,062,301 shares, with 51,046,726 shares pledged[12] - The second-largest shareholder, Wang Dengming, holds 7.43% of shares, totaling 45,534,495 shares[12] - The total number of shares with limited sale conditions for Tang Yong is 51,046,726, which are locked due to being a senior executive[16] - The total number of shares with limited sale conditions for Guo Lei is 35,774,906, with 7,933,446 shares released during the period[16] - The total number of shares with limited sale conditions for Liu Qilin is 24,845,520, which are also locked due to being a senior executive[16] - The total number of unrestricted shares held by the top ten shareholders includes 26,046,900 shares held by Chen Mei and 22,894,262 shares held by Wang Chuanying[15] - The total number of shares with limited sale conditions increased by 64,974,790 during the period, resulting in a total of 211,253,351 shares at the end of the reporting period[19] - The company has established a consistent action relationship among major shareholders, including Tang Yong, Wang Dengming, and Liu Qilin[15] - The company has a total of 154,212,007 shares with limited sale conditions at the beginning of the period[19] Strategic Initiatives - The company is actively engaging in strategic initiatives, including stock issuance and board restructuring, to enhance its operational capabilities and market position[20] - The company completed the election of its fifth board of directors and supervisory board, consisting of 6 non-independent directors and 3 independent directors[23] - The company received approval from the Shenzhen Stock Exchange for its application to issue shares to specific targets, confirming compliance with issuance conditions[20] - The company signed a tripartite supervision agreement for the special account storage of raised funds with the sponsor and the commercial bank[20] Research and Development - Research and development expenses increased to ¥46,379,511.10, up 16.4% from ¥39,826,443.24, indicating a focus on innovation[35] Financial Management - The company experienced a 44.12% reduction in financial expenses, totaling ¥7,092,225.58, due to decreased loan repayments and interest income from raised funds[11] - The company reported a decrease in accounts payable to ¥405,127,147.04 from ¥310,332,249.19, reflecting improved cash flow management[30] Audit Information - The company did not conduct an audit for the first quarter report[46]

Financial Performance - Maccura Biotechnology reported a revenue of 1.2 billion CNY for the fiscal year 2021, representing a year-over-year increase of 15% compared to 2020[39]. - The company achieved a net profit of 300 million CNY in 2021, which is a 20% increase from the previous year[39]. - The company's operating revenue for 2021 was ¥3,980,647,183.47, representing a 7.47% increase from ¥3,703,877,006.69 in 2020[46]. - The net profit attributable to shareholders for 2021 was ¥956,604,404.94, a 20.49% increase compared to ¥793,917,986.86 in 2020[46]. - The net cash flow from operating activities reached ¥1,616,683,215.88, marking a significant increase of 47.77% from ¥1,094,048,810.10 in 2020[46]. - The basic earnings per share for 2021 was ¥1.7308, up 20.77% from ¥1.4331 in 2020[46]. - The company reported a gross margin of 60% for 2021, consistent with the previous year, indicating stable cost management[39]. - The company achieved a revenue of 3.981 billion in 2021, a year-on-year increase of 7.47%, and a net profit of 957 million, up 20.49%[84]. - Sales revenue from self-developed products reached 2.3 billion, growing by 24.08%, while agency product sales declined by 9.76% to 1.635 billion[84]. - The gross profit margin for comprehensive sales increased from 53% to 58% year-on-year[84]. Market Expansion and Strategy - Maccura plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2023[39]. - The company is exploring potential acquisitions to enhance its product portfolio and expand its technological capabilities[39]. - The company aims to enhance its market competitiveness by promoting laboratory automation and self-sufficiency, thereby increasing its domestic market share[78]. - The company is focusing on enhancing its market presence and distribution capabilities, particularly in overseas markets, with 143 new overseas channels added during the reporting period[86]. - The company is actively pursuing strategic partnerships to facilitate market expansion and product development in emerging markets[179]. - The company is expanding its market reach with new registrations in various international markets, including significant numbers in Turkey, Egypt, and the Philippines[157]. Research and Development - The company has increased its R&D investment to strengthen its core technologies and reduce the risk of technology leakage[11]. - The company invested 25% to 30% of its net profit annually into R&D, totaling approximately 1 billion over the past five years, which is 13.4% of self-developed product revenue[92]. - The company has established three major R&D platforms covering biological raw materials, reagents, and instruments, with 906 R&D personnel accounting for 31.23% of total employees[92]. - The company has initiated a total of 346 research and development projects, expecting to deliver over 20 technological innovations and new products annually, with 433 patents held, including 203 invention patents[95]. - The company is focusing on developing advanced testing technologies, including direct chemiluminescence methods for various assays[172]. - The company is enhancing its research and development capabilities to support the launch of new diagnostic products[163]. Product Development and Innovation - The company has developed a comprehensive product line in in vitro diagnostic solutions, covering over 1,500 diagnostic reagents and more than 30 diagnostic instruments across nine major product platforms[77]. - The company has successfully launched innovative products, including the world's first creatinine reagent resistant to hydroxyphenylsulfonic acid interference and a new COVID-19 nucleic acid test kit approved for emergency use in Sichuan Province[79]. - The company has developed rapid and precise COVID-19 nucleic acid detection products, receiving registrations in multiple countries, which will strengthen its molecular detection product brand[132]. - The company is focusing on upgrading existing products based on customer and market demands, particularly in inflammation and diabetes testing[135]. - The company is expanding its product offerings in the field of autoimmune disease testing, with several new tests in the registration phase[138]. - The company has introduced a new series of COVID-19 related testing kits, including neutralizing antibody testing kits, which are also self-declared[172]. Regulatory Compliance and Quality Control - The company is committed to maintaining compliance with regulatory standards in the EU and EEA regions for its new products[164]. - The company has established a quality management system certified by TUV ISO9001 and ISO13485[97]. - The company is enhancing its quality control products, which are essential for maintaining the accuracy of diagnostic tests[168]. - The company actively participates in the formulation of industry standards, having completed the assignment of values for 33 standard substances or national standards during the reporting period[99]. Supply Chain and Operational Efficiency - The company is enhancing its supply chain efficiency and investing in cold chain logistics to improve product delivery[39]. - The company has a strong emphasis on procurement, ensuring quality by purchasing raw materials in bulk for six months to a year[80]. - The company operates under a sales-driven production model, aligning production plans with customer orders and demand forecasts[82]. - The company is transitioning its sales model from a mix of direct and distributor sales to primarily distributor-based sales, especially in the domestic market[83]. Challenges and Risks - The company acknowledges the risk of raw material supply shortages due to reliance on imports and is working to increase self-sufficiency in raw material production[15]. - The company is adapting its operational strategies in response to new regulations in the medical device industry, which may impact its business operations[7]. - The company is closely monitoring changes in industry regulations and adjusting its business strategies accordingly to mitigate potential risks[10].

Financial Performance - The company's revenue for Q3 2021 was ¥1,048,907,406.74, a decrease of 2.62% compared to the same period last year, while year-to-date revenue increased by 18.97% to ¥3,009,280,740.63[5] - Net profit attributable to shareholders for Q3 2021 was ¥264,476,232.47, up 3.39% year-on-year, with a year-to-date net profit of ¥796,158,158.88, reflecting a 40.65% increase[5] - The basic earnings per share for Q3 2021 was ¥0.4751, representing a 3.33% increase, while year-to-date earnings per share rose by 40.71% to ¥1.4326[5] - Total operating revenue for the current period reached ¥3,009,280,740.63, an increase of 18.9% compared to ¥2,529,544,954.27 in the previous period[29] - Net profit attributable to the parent company was ¥796,158,158.88, up 40.6% from ¥566,072,179.01 in the same period last year[34] - The company reported a comprehensive income total of ¥833,100,297.86, compared to ¥588,606,995.55 in the previous period, marking a 41.6% increase[34] - The basic earnings per share for the current period was ¥1.4326, compared to ¥1.0181 in the previous period, indicating a significant improvement[34] Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥878,776,421.53, showing a significant increase of 141.13%[11] - The net cash flow from operating activities for the current period is ¥878,776,421.53, a significant increase from ¥364,433,586.06 in the previous period, representing a growth of approximately 141.3%[39] - The total cash inflow from operating activities is ¥3,311,955,563.48, compared to ¥2,780,910,428.16 in the previous period, indicating an increase of about 19.1%[36] - Cash outflows from operating activities totaled ¥2,433,179,141.95, slightly up from ¥2,416,476,842.10, reflecting a marginal increase of 0.7%[36] - The net cash flow from investing activities is -¥409,468,914.15, worsening from -¥181,583,484.43 in the previous period[39] - Cash inflow from financing activities decreased to ¥1,005,667,444.25 from ¥1,333,875,959.73, a decline of approximately 24.5%[39] - The net cash flow from financing activities is -¥464,180,095.45, compared to -¥139,975,825.96 in the previous period, indicating a deterioration in financing cash flow[39] - The ending balance of cash and cash equivalents is ¥587,616,384.50, up from ¥470,707,986.10, showing an increase of about 24.8%[39] Assets and Liabilities - Total assets as of September 30, 2021, were ¥6,634,455,203.04, an increase of 4.23% from the end of the previous year[5] - The company's equity attributable to shareholders increased by 8.83% to ¥4,131,797,163.29 compared to the end of the previous year[5] - The company reported a significant increase in asset disposal gains of 686.48% year-on-year, amounting to ¥3,925,831.69[11] - The total assets of the company as of September 30, 2021, amounted to ¥6,634,455,203.04, an increase from ¥6,364,982,648.45 as of December 31, 2020[20] - The total liabilities decreased to ¥3,999,742,230.31 from ¥4,000,000,000, indicating a slight reduction[22] - Total liabilities decreased to ¥2,265,933,266.48 from ¥2,359,537,132.90, a reduction of approximately 4%[29] - The company's total operating costs were ¥1,993,276,148.82, which is an increase of 11.6% from ¥1,786,643,304.18 in the previous year[29] Research and Development - Research and development expenses for the year-to-date period reached ¥148,770,233.37, a 60.73% increase compared to the previous year, indicating a strong commitment to product development[11] - Research and development expenses increased to ¥148,770,233.37, representing a 60.8% rise from ¥92,561,483.33 in the previous year[29] Shareholder Information - The company reported a total of 164,063,304 shares with restricted trading, with 9,021,111 shares released during the period[19] - The number of shares held by the top ten shareholders includes significant holdings such as 51,046,726 shares by Tang Yong[16] Other Financial Metrics - The company's cash and cash equivalents were reported at ¥608,821,058.49, slightly down from ¥612,065,315.96 in the previous year[20] - Accounts receivable decreased to ¥1,983,891,687.64 from ¥2,020,529,599.32 year-over-year, indicating a reduction of approximately 1.8%[20] - Inventory increased to ¥1,129,744,474.27 from ¥1,074,837,340.90, reflecting a growth of about 5.1%[22] - The company's non-current assets totaled ¥2,590,712,972.73, up from ¥2,339,770,779.54, representing an increase of approximately 10.7%[22] - The company has a total of 4,043,742,230.31 in current assets, showing a marginal increase from 4,025,211,868.91[22] - The company’s short-term borrowings decreased to ¥768,444,577.76 from ¥921,547,655.36, reflecting a reduction of approximately 16.6%[22] - Minority interests increased to ¥236,724,773.27 from ¥208,742,321.89, reflecting a growth of 13.4%[29] Audit Information - The company has not undergone an audit for the third quarter report[49]